About usRespiratory infectionsOur Technology

About us

Signia Therapeutics proposes a breakthrough strategy for the development of a new generation of antivirals which will target the infected host cell rather than viral determinants.

Learn More

Respiratory infections

A major public health issue - Innovative & efficient antiviral Strategies are necessary

Learn More

Our Technology

A novel & Proprietary Technology for Drug Repurposing

Learn More

Breakthrough Solution for Respiratory Infections

Contact us
Signia Therapeutics proposes a breakthrough strategy for the development of a new generation of antivirals which will target the infected host cell rather than viral determinants. This novel proprietary development strategy has already a proven track record and is based on a solid set of proofs of concept.

About us

Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1, that has and will continue to develop a proprietary platform to identify new products for the respiratory tract virus market where new approaches are greatly needed. Signia Therapeutics benefits from well established academic and industrial partnerships of VirPath laboratory, which contribute to significantly de-risking the path […]

Respiratory infections

Acute respiratory tract infection Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens represent a major public health issue and have a large socio-economic impact. ARTI caused by several viruses including influenza […]

Technology

To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company’s proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for […]

Team

President   Michel Cousineau (MBA) has over 35 years of experience in corporate and business development in the health care sector for emerging companies as well as with subsidiaries of large international biopharmaceutical companies. He brings a vast network of contacts throughout the industry at various level of management and with investment groups.     […]

Our Blog

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.